Thymoglobulin Capping Defects Cited In Aventis Pasteur Warning Letter
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA cites Genzyme’s Thymoglobulin contract manufacturer Aventis Pasteur for failures related to its quality control unit. Warning letter also points to quality control deficiencies involving haemophilius b conjugate vaccine and rabies vaccine.